The main cytotoxic agents approved for CRC are platinum-derivatives, 5-fluorouracil (5-Fu), capecitabine, and irinotecan, combined with targeted therapies against epidermal growth factor receptor (anti-EGFR) or vascular endothelial growth factor (anti-VEGF) [65]. The gene discussed is EGFR; the disease is colorectal carcinoma.